Drug Trial Radar · NCT01181986
The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes
Last checked: Nov 19, 2026Latest source record: May 20, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
76
Actual
Start
Aug 2010
Primary completion
Dec 2012
Study completion Dec 2012
Sponsor
- Lead sponsor
- Carl T. Hayden VA Medical CenterFederal agency
- Sponsor type
- Federal agency
- Collaborators
- American Diabetes Association; Amylin Pharmaceuticals, LLC.
- First posted
- Aug 16, 2010
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Basic science
- Who can join
- All sexes, from 35 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this investigation is to evaluate whether exenatide, a type 2 diabetes medication, will improve the function of the innermost part of the arterial wall called the endothelium after a fat-enriched meal and to determine how this occurs. The results of this study will help to determine and understand a novel action of this group of diabetes medications based on the action of naturally occuring gut substances called incretins. This may have a significant impact on cardiovascular health in patients with early and longstanding diabetes.
Conditions
- Type 2 Diabetes Mellitus
Interventions
Exenatide SCDrug
Exenatide 5-10 ug sc BID/10 days
Exenatide IVDrug
50 ng/min intravenously for 45 minutes on 2 out of 3 study visits separated by 5-10 days
Placebo SCDrug
Placebo sc BID/10days
Exendin-9Drug
Primed (6,000 pM/kg), continuous (600 pM/kg) intravenous infusion for 75 minutes on 1 out of 3 study visits.
Placebo IVDrug
Intravenous infusion for 45 minutes on 1 out of 3 visits
Primary outcomes
What the sponsor says the trial is designed to measure.
- Reactive Hyperemia Index (RHI)Time frame: 0, 2, 4, 6 and 8 hours on Day 11 (Sub-study 1); 0 and 120 minutes on test Days 1, 2 & 3 (Sub-study 2)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Phoenix VA Medical Center
Phoenix, Arizona
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.